OMRON empowers engagement with AliveCor on remote cardiovascular condition management

 KUALA LUMPUR, Nov 24 -- OMRON Healthcare Co Ltd has announced additional investment into AliveCor by its parent company, OMRON Corporation, as part of US$65 million series E funding for the leader in AI-based personal electrocardiogram (ECG) technology. (US$1 = RM4.09)

According to a statement, OMRON led this round of investment, reinforcing the cross-company collaboration that began in 2017.

The companies continue to build on their global alliance to accelerate development of solutions for cardiovascular disease management and remote patient monitoring utilising ECG technology.

“OMRON is committed to developing life-saving cardiovascular health technologies in pursuit of our 'Going for Zero' vision to eliminate heart attacks and strokes,” said OMRON Healthcare president and chief executive officer, Isao Ogino.

“Over one billion adults are hypertensive worldwide, and their risk of stroke is nearly five times greater if they also suffer from Afib (atrial fibrillation).

“The ability to monitor both blood pressure and heart rhythm at home is essential for early detection, treatment and management of these cardiovascular health conditions.

“We continue to explore and develop new technologies to enhance the accessibility of home monitoring that help people to manage their condition, and will engage partners like AliveCor to ensure this technology is best-in-market, further accelerating our remote patient monitoring business to achieve our goal.”

OMRON's expanded investment into AliveCor builds upon the companies' ongoing collaboration.

OMRON Healthcare is a global leader in the field of clinically proven, innovative medical equipment for health monitoring and therapy.

-- BERNAMA